Kawagishimachi, Chuo-Ku
Niigata 951-8566
Japan
Niigata Cancer Center Hospital
Immune checkpoint inhibitor, Atezolizumab, Carboplatin, nab-paclitaxel, Nonsquamous non-small cell lung cancer
locally advanced, Non-small cell lung cancer (NSCLC), older patients, chemoradiotherapy, daily low-dose carboplatin, carboplatin plus nab-paclitaxel
Non-small cell lung cancer, Performance status 2, Immune checkpoint inhibitors, Real-world evidence, First-line therapy